



**VIJAYA**<sup>®</sup>  
**DIAGNOSTIC**  
**CENTRE**

**February 12, 2025**

To,  
The Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051  
**NSE Symbol: VIJAYA**

To,  
The Corporate Relations Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> floor, Dalal Street,  
Mumbai - 400 001  
**BSE Scrip Code: 543350**

Dear Sir/Madam,

**Subject: Integrated Filing (Financial) for the third quarter and nine months ended December 31, 2024**

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2 January 2025, we are submitting herewith the Integrated Filing (Financial) for the third quarter and nine months ended December 31, 2024.

Kindly take the same on record.

Yours Faithfully,  
For **Vijaya Diagnostic Centre Limited**

**Hansraj Singh**  
**Company Secretary & Compliance Officer**  
**M. No. F11438**

Encl.: as above

# B S R and Co

Chartered Accountants

Salarpuria Knowledge City, Orwell  
B Wing, 6th Floor, Unit-3, Sy No. 83/1  
Plot No. 02, Raidurg  
Hyderabad – 500 081, India  
Telephone + 91 407 182 2000  
Fax + 91 407 182 2399

## Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Company”) for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R and Co**

*Chartered Accountants*

Firm’s Registration No.:128510W

**BALKISHA** Digitally signed by  
**N KABRA** BALKISHAN KABRA  
Date: 2025.02.12  
13:22:58 +05'30'

**Balkishan Kabra**

*Partner*

Hyderabad

12 February 2025

Membership No.: 221202

UDIN:25221202BMOCFS7207

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,  
Western Express Highway, Goregaon (East), Mumbai - 400063



Vijaya Diagnostic Centre Limited  
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India  
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and year-to-date ended 31 December 2024

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	15,625.54	16,860.65	12,911.78	46,728.51	38,397.07	52,502.27
	(b) Other income	499.05	480.36	525.36	1,361.94	1,803.34	2,143.89
	<b>Total income</b>	<b>16,124.59</b>	<b>17,341.01</b>	<b>13,437.14</b>	<b>48,090.45</b>	<b>40,200.41</b>	<b>54,646.16</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	1,968.76	2,132.97	1,561.80	5,816.95	4,571.31	6,284.97
	(b) Employee benefits expense	2,615.59	2,538.18	2,238.08	7,633.06	6,405.10	8,646.48
	(c) Finance costs	626.40	606.86	604.92	1,838.03	1,776.02	2,370.82
	(d) Depreciation and amortisation expense	1,685.66	1,536.69	1,440.29	4,741.22	4,049.87	5,540.59
	(e) Other expenses	4,793.47	5,173.45	4,003.32	14,442.53	11,926.15	16,351.13
	<b>Total expenses</b>	<b>11,689.88</b>	<b>11,988.15</b>	<b>9,848.41</b>	<b>34,471.79</b>	<b>28,728.45</b>	<b>39,193.99</b>
<b>3</b>	<b>Profit before tax and exceptional items [1-2]</b>	<b>4,434.71</b>	<b>5,352.86</b>	<b>3,588.73</b>	<b>13,618.66</b>	<b>11,471.96</b>	<b>15,452.17</b>
<b>4</b>	<b>Exceptional items (Refer Note 4)</b>	-	-	205.00	-	205.00	205.00
<b>5</b>	<b>Profit before tax [3-4]</b>	<b>4,434.71</b>	<b>5,352.86</b>	<b>3,383.73</b>	<b>13,618.66</b>	<b>11,266.96</b>	<b>15,247.17</b>
<b>6</b>	<b>Tax expense</b>						
	(a) Current tax	864.00	1,205.00	907.00	2,938.00	2,478.93	3,209.93
	(b) Deferred tax	217.46	198.06	(47.91)	491.30	378.74	577.04
	<b>Total tax expense</b>	<b>1,081.46</b>	<b>1,403.06</b>	<b>859.09</b>	<b>3,429.30</b>	<b>2,857.67</b>	<b>3,786.97</b>
<b>7</b>	<b>Profit for the period/year [5 - 6]</b>	<b>3,353.25</b>	<b>3,949.80</b>	<b>2,524.64</b>	<b>10,189.36</b>	<b>8,409.29</b>	<b>11,460.20</b>
<b>8</b>	<b>Other comprehensive income</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	(a) Remeasurement of defined benefit liability / (asset)	(3.72)	(4.57)	6.48	(12.86)	19.43	(16.62)
	(b) Income-tax relating to above item	0.94	1.15	(1.63)	3.24	(4.89)	4.18
	<b>Other comprehensive income for the period/year (net of tax)</b>	<b>(2.78)</b>	<b>(3.42)</b>	<b>4.85</b>	<b>(9.62)</b>	<b>14.54</b>	<b>(12.44)</b>
<b>9</b>	<b>Total comprehensive income for the period/year [7 + 8]</b>	<b>3,350.47</b>	<b>3,946.38</b>	<b>2,529.49</b>	<b>10,179.74</b>	<b>8,423.83</b>	<b>11,447.76</b>
<b>10</b>	<b>Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)</b>	1,026.29	1,026.22	1,023.09	1,026.29	1,023.09	1,023.46
<b>11</b>	<b>Other equity</b>						64,308.65
<b>12</b>	<b>Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 5)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	3.26	3.85	2.47	9.93	8.23	11.21
	- Diluted (in Rs.)	3.26	3.84	2.46	9.91	8.20	11.18

Notes:

- The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).
- The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 12 February 2025. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 31 December 2024. An unmodified report has been issued by them thereon.
- The Company has one reportable segment (viz. Diagnostic services) as per the requirements of Ind AS 108 "Operating Segments".
- During the previous year, the Company incurred an amount of Rs. 205 lakhs for the evaluation of various acquisitions towards financial, legal and tax due diligence and for market study on the diagnostic business in target geographies. These expenses had been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company.
- During the quarter and year-to-date ended 31 December 2024, the Company has issued 7,652 and 2,83,769 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
- The Board of Directors of the Company at their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") wherein Medinova Diagnostic Services Limited (Subsidiary Company) would merge into the Company with effect from 01 April 2024 ("the Appointed Date") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company has received letter with "no adverse observations" from the BSE Limited, NSE Limited and SEBI on December 05, 2024, and further the scheme is subject to the approval of Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.
- The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of  
Vijaya Diagnostic Centre Limited

SURA  
SURENDRANATH  
REDDY

Digitally signed by SURA  
SURENDRANATH REDDY  
Date: 2025.02.12  
12:52:59 +05'30'

Dr. S. Surendranath Reddy

Executive Chairman  
DIN Number: 00108599

Place: Hyderabad  
Date: 12 February 2025

## Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 31 December 2024 and year to date results for the period from 01 April 2024 to 31 December 2024 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

#### Parent

- a. Vijaya Diagnostic Centre Limited

#### Subsidiaries

- b. Medinova Diagnostic Services Limited
- c. VDC Diagnostic (Karnataka) LLP
- d. Medinova Millenium MRI Services LLP
- e. P H Diagnostic Centre Private Limited
- f. Namrata Diagnostic Centre Private Limited (Struck off on 06 April 2024)
- g. Doctorslab Medical Services Private Limited (Struck off on 06 April 2024)

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,  
Western Express Highway, Goregaon (East), Mumbai - 400063

**Limited Review Report (Continued)**

**Vijaya Diagnostic Centre Limited**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of 3 Subsidiaries included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 1,325.29 lakhs and Rs. 4,190.28 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 201.87 lakhs and Rs. 772.80 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 201.87 lakhs and Rs. 772.80 lakhs for the quarter ended 31 December 2024 and for the period from 01 April 2024 to 31 December 2024 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

*Chartered Accountants*

Firm's Registration No.:128510W

**BALKISHA** Digitally signed by  
BALKISHAN KABRA  
**N KABRA** Date: 2025.02.12  
13:23:58 +05'30'

**Balkishan Kabra**

*Partner*

Hyderabad

12 February 2025

Membership No.: 221202

UDIN:25221202BMOCFT2340



**VIJAYA  
DIAGNOSTIC  
CENTRE**

Vijaya Diagnostic Centre Limited  
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India  
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter and year-to-date ended 31 December 2024

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	16,898.26	18,294.82	13,269.16	50,814.76	39,260.01	54,780.53
	(b) Other income	469.70	450.99	511.00	1,277.09	1,756.77	2,081.80
	<b>Total income</b>	<b>17,367.96</b>	<b>18,745.81</b>	<b>13,780.16</b>	<b>52,091.85</b>	<b>41,016.78</b>	<b>56,862.33</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	2,085.25	2,298.81	1,598.80	6,259.83	4,662.40	6,543.84
	(b) Employee benefits expense	2,855.48	2,783.72	2,302.84	8,375.00	6,569.69	9,021.86
	(c) Finance costs	681.97	646.84	606.07	1,955.32	1,779.57	2,398.98
	(d) Depreciation and amortisation expense	1,830.46	1,683.74	1,454.10	5,177.60	4,069.89	5,699.62
	(e) Other expenses	5,244.34	5,614.00	4,136.97	15,744.75	12,248.99	17,124.94
	<b>Total expenses</b>	<b>12,697.50</b>	<b>13,027.11</b>	<b>10,098.78</b>	<b>37,512.50</b>	<b>29,330.54</b>	<b>40,789.24</b>
<b>3</b>	<b>Profit before tax and exceptional items [1 - 2]</b>	<b>4,670.46</b>	<b>5,718.70</b>	<b>3,681.38</b>	<b>14,579.35</b>	<b>11,686.24</b>	<b>16,073.09</b>
<b>4</b>	<b>Exceptional items (Refer Note 4)</b>	-	-	205.00	-	205.00	205.00
<b>5</b>	<b>Profit before tax [3 - 4]</b>	<b>4,670.46</b>	<b>5,718.70</b>	<b>3,476.38</b>	<b>14,579.35</b>	<b>11,481.24</b>	<b>15,868.09</b>
<b>6</b>	<b>Tax expense</b>						
	(a) Current tax	934.41	1,282.62	922.66	3,177.90	2,499.74	3,319.95
	(b) Deferred tax, net	206.16	223.61	(46.40)	508.57	385.55	584.43
	<b>Total tax expense</b>	<b>1,140.57</b>	<b>1,506.23</b>	<b>876.26</b>	<b>3,686.47</b>	<b>2,885.29</b>	<b>3,904.38</b>
<b>7</b>	<b>Profit for the period/year [5-6]</b>	<b>3,529.89</b>	<b>4,212.47</b>	<b>2,600.12</b>	<b>10,892.88</b>	<b>8,595.95</b>	<b>11,963.71</b>
<b>8</b>	<b>Other comprehensive income</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	(a) Remeasurement of the defined benefit obligations	(3.72)	(4.57)	6.48	(12.86)	19.43	(14.99)
	(b) Income-tax relating to above item	0.94	1.15	(1.63)	3.24	(4.89)	3.77
	<b>Other comprehensive income for the period/year (net of tax)</b>	<b>(2.78)</b>	<b>(3.42)</b>	<b>4.85</b>	<b>(9.62)</b>	<b>14.54</b>	<b>(11.22)</b>
<b>9</b>	<b>Total comprehensive income for the period/year [7+8]</b>	<b>3,527.11</b>	<b>4,209.05</b>	<b>2,604.97</b>	<b>10,883.26</b>	<b>8,610.49</b>	<b>11,952.49</b>
	<b>Profit for the period attributable to:</b>						
	Owners of the Company	3,515.63	4,193.64	2,584.87	10,843.79	8,537.44	11,882.53
	Non controlling interests	14.26	18.83	15.25	49.09	58.51	81.18
	<b>Other comprehensive income attributable to:</b>						
	Owners of the Company	(2.78)	(3.42)	4.85	(9.62)	14.54	(11.68)
	Non controlling interests	-	-	-	-	-	0.46
	<b>Total comprehensive income attributable to:</b>						
	Owners of the Company	3,512.85	4,190.22	2,589.72	10,834.17	8,551.98	11,870.85
	Non controlling interests	14.26	18.83	15.25	49.09	58.51	81.64
<b>10</b>	<b>Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)</b>	<b>1,026.29</b>	<b>1,026.22</b>	<b>1,023.09</b>	<b>1,026.29</b>	<b>1,023.09</b>	<b>1,023.46</b>
<b>11</b>	<b>Other equity</b>						<b>64,695.88</b>
<b>12</b>	<b>Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 5)</b>	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	3.42	4.09	2.53	10.57	8.35	11.62
	- Diluted (in Rs.)	3.42	4.08	2.52	10.55	8.33	11.59

**Notes:**

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the Act) read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).
2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 12 February 2025. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 31 December 2024. An unmodified report has been issued by them thereon.
3. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
4. During the previous year, the Company incurred an amount of Rs. 205 lakhs for the evaluation of various acquisitions towards financial, legal and tax due diligence and for market study on the diagnostic business in target geographies. These expenses had been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company.
5. During the quarter and year-to-date ended 31 December 2024, the Company has issued 7,652 and 2,83,769 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
6. The Board of Directors of the Company in their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") wherein Medinova Diagnostic Services Limited (Subsidiary Company) would merge into the Company with effect from 01 April 2024 ("the Appointed Date") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company has received letter with "no adverse observations" from the BSE Limited, NSE Limited and SEBI on December 05, 2024, and further the scheme is subject to the approval of Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.
7. The results of the Group are available for investors at [www.vijayadiagnostic.com](http://www.vijayadiagnostic.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

*for and on behalf of the Board of Directors of*  
**Vijaya Diagnostic Centre Limited**

SURA  
SURENDRANA  
TH REDDY

Digitally signed by  
SURA SURENDRANATH  
REDDY  
Date: 2025.02.12  
12:54:12 +05'30'

**Dr. S. Surendranath Reddy**  
Executive Chairman  
DIN Number: 00108599

Place: Hyderabad

Date: 12 February 2025

- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT etc. – Not Applicable**
  
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – Not Applicable (No default)**
  
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half – yearly filings i.e. 2<sup>nd</sup> and 4<sup>th</sup> quarter) – Not Applicable**
  
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG – WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e. 4<sup>th</sup> quarter) – Not Applicable**